Pomerantz LLP announced investigations into securities fraud claims against SELLAS Life Sciences, JinkoSolar, and Stitch Fix. The investigation into SELLAS focuses on delayed release of phase 3 clinical trial results for Galinpepimut-S, which triggered an 13.15% stock price decline on August 28, 2026.
SLS
SELLAS Life Sciences Group, Inc. · NASDAQ
Sign up free to see this.
Mkt Cap
$2.3B
Volume
2.9M
52W High
$15.88
52W Low
$1.39
PE Ratio
—
Avg Vol
5.9M
As of 10/23/26
Div Yield
—
Beta
2.08
As of 10/23/26
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
At least 5 tagged posts are needed.
How do you feel about SLS?
Latest news
News ›Headlines link to the publisher. Not investment advice.
Board · 0 threads
Open board ›No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Community
7 daysNo sentiment yet
Posts 24h
0
Replies 24h
0
Watchers
0
Board · $SLS · 0 threads
Sign in to post on $SLS
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.